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Abstract 
Objective: The primary objective of the current study is to evaluate the existing healthcare costs 
that healthcare emergency departments (EDs) and hospitals incur as a result of ED visits from 
chronic obstructive pulmonary disease (COPD) exacerbations and hospital admissions for 
congestive heart failure (CHF) within the medium size hospitals in the state of Florida in 2018. 
These data insights can determine better where telehealth might be used to save hospitals more 
money. 
  
Methods: The study design chosen was a retrospective cohort study analysis of HCUP archival 
billing data that examines specific databases- SID and SEDD- for CHF admissions and COPD 
ER visits for all adult individuals age 18 years and older in the calendar year 2018.  
 
Results: For CHF admissions, the total number of hospitals included totaled 182 facilities. The 
the total median charges for CHF admissions was $27M. The total median cost was 3.4M. The 
median cost per CHF admission was $11,000. In terms of COPD ER visits, the total number of 
hospitals included totaled 163 hospitals. The total median charges was 3.6M. The total median 
cost was $278,000. The median cost per visit was $599. 
  
Conclusion: CHF admissions cost more money than the COPD ER visit ($8B vs. $822M, 
respectively). Telehealth services offer annual significant cost savings for both conditions ($1.8B 
and $274M, respectively). 
 
KeyWords: congestive heart failure, chronic obstructive pulmonary disease, hospital admission, 
hospital readmission, CHF admission, COPD ER visits, hospital readmission reduction program, 
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CHAPTER I - INTRODUCTION 
1.1 Background and Need 
In 2014, healthcare costs in the United States were estimated at $3.0 trillion (17.5 percent 
of the US GDP), compared to $260 billion (9.18 percent of the GDP) in 1980. Those figures are 
expected to approach 30 percent of GDP in 2040. In 2014, Medicare reimbursed 4,700 hospitals 
around $173 billion for inpatient and outpatient services, a 4 percent rise from the prior year 
(Chamberlain et al., 2018). Hospital admission and readmission are important causes of rising 
healthcare costs in hospitals in the United States and is considered an essential measure for 
patient care quality (Bailey et al., 2019). Mayo Clinic outlines hospital readmission as patient 
admission to a hospital within thirty days after being released from an initial hospital stay. The 
CMS uses the thirty-day readmission rate as a standard benchmark. “Readmission rates at the 
80th percentile or lower are considered optimal by CMS” (Mayo Clinic, 2020). 
Heart failure is an extremely widespread condition associated with notable patients 
morbidity and mortality. The HF rate rises significantly with age, with more than 60 percent of 
patients with HF aged above 65 years, which will predict to increase in the future due to the 
aging of the population in the U.S. Furthermore, the prognosis of patients diagnosed with 
primary HF is relatively poor, half of all cases with HF are dying within five years of the initial 
diagnosis (Kilgore et al., 2017). Therefore, HF patient care puts a significant economic burden 
on the healthcare system. Despite vital therapeutic progressions, cases with HF need frequent 
hospital admissions for cardiovascular conditions such as congestion, ischemia, uncontrolled 
hypertension, arrhythmias, and hypervolemia, as well as non-CV comorbidities. Researches have 




them are hospitalized more than three times within five years of initial diagnosis (Kilgore et al., 
2017). 
Patients diagnosed with COPD who suffer from exacerbations frequently need hospital 
emergency department (ED) visits and probably hospital admissions because these conditions 
may advance to respiratory failure. Studies have noted that once a patient has an exacerbation 
episode, it will make this patient more exposed to future exacerbations. Hospital admissions 
correlated with COPD remain to be a considerable part of healthcare expenditures. In 2010, 
patients with COPD cost the healthcare system in the U.S around 50 Billion with increasing costs 
in the following years because the exacerbation frequency and severity of COPD become worse. 
The majority of spending is linked to admissions that accounts for >70% of COPD-related care 
costs. Reducing the quantity of preventable admissions could drive cost cuts and allocate the 
resources to preventive care in patients suffering from COPD (Kumbhare, Beiko, Wilcox & 
Strange, 2015). 
Healthcare costs due to hospital readmissions are increasing in several countries in the 
world. Hospital readmissions impose significant patient morbidity, mortality, and financial 
burden on the healthcare system. The Medicare Payment Advisory Commission (MedPAC) 
evaluated Medicare pays $12 billion yearly for hospital readmissions thought to be potentially 
preventable (Shulan, Gao & Moore, 2013). Gupta and Fonarow (2018) noted that approximately 
79 percent of all hospitals were penalized for readmission rates that exceeded targets. This 
accounted for a total of $528 million of Medicare payments withheld (Gupta & Fonarow, 2018). 
This figure then climbed to $564 million in 2018 according to research conducted by Zohrabian 
and colleagues (2018). For instance, there are over 1 million CHF hospitalizations per year, and a 




preventable, the potential for reduced admissions would approach 175,000 CHF hospital 
admissions per year (Chamberlain et al., 2018). 
Payers and researchers all over the world are trying to find ways to reduce hospital 
admissions and readmissions. Also, reducing inpatient readmission in US hospitals attracts the 
attention of policymakers when trying to improve outcomes and utilization. Researchers found 
that the US has an enormous readmission rate compared with other countries worldwide (Shulan, 
Gao & Moore, 2013). This is why patient readmission rates have come under extreme scrutiny 
over the last decade; but, readmission cost studies are still limited, and outcomes of savings 
remain unclear. In 2009, the CMS started to track and report hospital readmission rates and their 
causes. In October 2012, the CMS decided to penalize and decrease payments to healthcare 
systems with unnecessary readmissions for specific conditions such as heart diseases (acute 
myocardial infarction, congestive heart failure), septicemia, pneumonia, and Chronic Obstructive 
Pulmonary Disease (COPD) (Shulan, Gao & Moore, 2013).  
The main causes of hospital readmission in the U.S. are pneumonia, septicemia, COPD 
exacerbation, and congestive heart failure (Jiang et al., 2018). COPD exacerbation is a leading 
cause of hospital readmissions accounted for 21.5 percent of hospital readmissions with an 
approximated cost of $1 billion annually. CHF is considered the most common reason for 
Medicare patient readmissions in the USA (Jiang et al., 2018). The American Heart Association 
estimated the prevalence of heart failure to be around 5.7 million, and an approximated 1 million 
hospital stays were related to CHF (Chamberlain et al., 2018). Therefore, this study examined 
hospital admission costs for CHF patients and COPD ED visits. Chamberlain and colleagues 




The CMS designed the Hospital Readmissions Reduction Program (HRRP) to help 
hospitals enhance care coordination and communication to engage caregivers and patients in 
hospital discharge plans, thereby also possibly reducing avoidable readmissions. There is a 
strong link between hospital performance and the excess readmission ratio (ERR), which 
estimates a hospital’s relative performance (CMS, 2020). Sometimes, traditional healthcare 
approaches that focus on managing a particular chronic disease cannot successfully satisfy 
effective disease management elements. For example, COPD patients frequently have 
multimorbidities.  
Adopting an innovative patient-centered approach is imperative to improve patient care 
outcomes and reduce hospital readmission and, ultimately, healthcare costs. Telehealth or other 
types of virtual contacts have been found to be effective in decreasing hospital readmissions and 
ED visits (Deasfernandes, 2020). On the other hand, telehealth interventions significantly 
improved quality of life and reduced COPD severity, and they also found fewer hospital 
presentations (Newham et al., 2017). Telehealth implementation is a tool to exchange 
information between doctor and patient through video conferencing and virtual contacts. It also 
facilitates patient-centered care and offers new approaches to supports chronic disease 
management, such as COPD and CHF (Gaveikaite et al., 2020).  
As an overview of the telehealth systems’ use to reduce COPD exacerbations, ED visits, 
hospital admissions, and hospital readmissions, the research evidence is generally supportive 
(Farias et al., 2018; Sanchez-Nieto et al., 2016). Likewise, cost benefits are suggested by limited 
research as well (Vasilopoulou et al., 2017). The mechanism by which these programs offer 
benefits appear to be through enhanced adherence to care recommendation, increased patient 




However, research has yet to define specific subsets of COPD patients or specific situations 
where these programs might be the most useful. 
This study was designed to help healthcare professionals and administrators make 
informed decisions when implementing a telehealth program in an average-sized community 
hospital in Florida by comparing the total gross costs of hospital admissions related to CHF and 
COPD ER visits. For instance, if we compare the costs of hospital admission due to CHF and ED 
visits in a medium-sized hospital in Florida and find that the cost of CHF admission is more; 
then it may be cost-efficient to implement a telehealth program for these patients to lower the 
overall healthcare costs. 
1.2 Problem Statement 
Hospital admission due to CHF and COPD ED visits has been known to be an important 
factor in skyrocketing healthcare costs in the United States (Kilgore et al., 2017). Improper 
treatments for HF and COPD in the ER, and Unplanned readmissions can extremely deteriorate 
both the patient's quality of life and the healthcare system’s financial health (Shulan, Gao & 
Moore, 2013). Studies showed that patients with COPD and heart attacks have the highest 
readmission rate, at 23% to 26% (Hamm & Loria, 2019). Telehealth or other types of virtual 
contacts have been shown to decrease hospital admissions, readmissions and ED visits. Many 
studies have discussed and proved the influence of telehealth on health outcomes, with a 
reduction in hospital readmissions and patient mortality (Kvedar, Coye & Everett, 2014). 
However, there are many populations that could be targeted for such a program. In the existing 
literature, researchers have typically examined the cost of admission, and the cost of ED visits 
separately. Since data are sourced from different populations, it’s hard to use these data for 




benefits for these interventions compare for the average community hospital in Florida. 
1.3 Study Objectives 
This study’s objective is to compare the gross costs of hospital admissions due to CHF and the 
ED visits for COPD patients in the same hospitals in Florida over the same period of time. 
Telehealth is an attractive approach to decrease hospital admission and readmission related to these 
two conditions, which will be explained in more detail in the literature review section. Therefore,  
comparing the costs for both conditions will help healthcare administrators in the decision-making 
process to implement a telehealth program or virtual interventions to reduce the cost of care. In 
other words, this study will examine the cost of admission for patients with CHF and the cost of 
ED visits for patients with COPD separately and compare them to find out which one of the two 
conditions could save more money to a medium-sized hospital in Florida if a telehealth program 
were implemented. The project data will be extracted from the statewide representative databases 
(HCUP) for COPD ED visits and CHF admissions in the calendar year 2018 in Florida. A 
retrospective analysis of HCUP archival billing data will be performed.  
1.4 Research Questions  
The study proposes to satisfy the following questions: 
1. What is the average per-patient cost of a single admission for CHF patients in a medium-
sized hospital in Florida in 2018? 
Hypothesis: The average cost for CHF admission is $13,000 (Becker’s Hospital Review, 
2015). 
2. What is the average per-patient cost of a single ED visit for COPD patients in a medium-
sized hospital in Florida in 2018? 




3. Using simulated data, which conditions would save the most money for the average 
medium-sized hospital? 
Hypothesis: CHF cost the medium-sized hospital in Florida more money and promise 
more savings if a hospital implement a telehealth program. 
1.5 Population 
This study includes all adult patients ≥18 years of age who were admitted with a primary 
diagnosis of CHF and patients with COPD diagnosis coming to the ER based on (International 
Classification of Diseases, Tenth Edition, Clinical Modification [ICD-10-CM] codes in the state 
of Florida in medium sized hospitals in the calendar year 2018. Since the purpose of this study is 
to simply measure cost per episode, patients who stay for an extended number of months each 














CHAPTER II - LITERATURE REVIEW 
In the U.S., healthcare expenditures comprise a significant part of the nation’s gross 
domestic product (GDP). In 2016, the U.S. spent $3.3 trillion on healthcare, which represented 
17.9 percent of GDP. But despite spending nearly twice as much per capita than the next highest 
nation on healthcare, quality and access remain notably subpar (Zohrabian, Kapp & Simoes, 
2018). Understanding this, efforts have been made to reduce costs and improve the efficiency of 
healthcare through incentive programs like the Hospital Readmission Reduction Program 
(HRRP), which penalizes hospitals for early readmissions of specific conditions. Among these 
conditions, congestive heart failure (CHF) and chronic obstructive pulmonary disease (COPD) 
are among those accounting for significant healthcare costs (Chamberlain, Sond, Mahendraraj, 
Lau, & Siracuse, 2018; Rezaee et al., 2018). 
Efforts to reduce healthcare costs for both conditions have been pursued by efforts to 
identify better factors that result in worsening severity. For congestive heart failure, this has 
involved finding specific demographic, clinical, and management issues that lead to general 
declines in function and hospital admission (Wu, et al., 2019). Hospital admissions for 
congestive heart failure are notably costly, with the average cost per admission for a congestive 
heart failure patient being around $15,000 (Kilgore, Patel, Kielhorn, Maya, & Sharma, 2017). 
Some have questioned whether reducing hospitalizations to a significant degree is worthwhile of 
cost-effective overall (Blood, Fraiche, & Eapen, 2017). However, most researchers support the 
notion that this is n attainable goal and that efforts to do so would reduce healthcare expenditures 
while improving quality of life (Lin, et al., 2016).  
Healthcare providers and systems have similar concerns about patients known to have 




well during exacerbations. These presentations also impose significant healthcare systems costs 
while reducing the patient quality of life (Newham et al., 2017). Researchers have estimated that 
for every 1,000 patients with COPD, nearly three percent are hospitalized each year. At the same 
time, almost four percent present to the emergency room for urgent evaluation and care 
(Gershon, Thiruchelvam, Moineddin, Zhao, Hwee, & To, 2017). In the U.S., this has resulted in 
tremendous costs. While direct costs for each COPD patient each year is over $10,000, 
hospitalization costs are nearly $7,000 of this amount (Rehman et al., 2020). Thus, it is evident 
that interventions or other approaches that improve functional capacities in COPD patients 
and/or reduce exacerbations will result in notable cost savings as well.  
 In addition to admissions for CHF and COPD, readmissions shortly after discharge are 
also a concerning issue. For hospitals, reducing readmissions for these specific conditions has 
proved challenging, with roughly 79 percent being penalized under HRRP in 2017. Incentive 
structures of the HRRP have failed to produce the results wanted (Gupta & Fonarow, 2018). 
Newer technologies and strategies are therefore needed, and telehealth offers one such approach 
that might be effective. Telehealth has increased in use over the last decade, and it has the 
potential to reduce costs, improve productivity, and engage patients in their own care (Snoswell 
et al., 2020). Understanding that healthcare expenditures are expected to rise progressively over 
the next ten years, exploring telehealth solutions is worthwhile, especially from a cost 
perspective (Deasfernandes, 2020).  
 In order to appreciate the current landscape regarding these subjects, a literature review 
was conducted to explore the subjects of readmission rates and costs related to CHF and COPD, 
emergency department (ED) visits for COPD exacerbations, the benefits and shortcomings of the 




databases were searched for relevant primary research, which included ProQuest, Google 
Scholar, CINAHL, and PubMed. Search terms included “congestive heart failure,” “chronic 
obstructive pulmonary disease,” “hospital admission,” “hospital readmission,” “hospital 
readmission reduction program,” “CHF admission,” “COPD ER visits,” “telehealth,” 
“telemedicine,” “COPD exacerbations,” “cost benefits,” and “cost savings.” Terms were 
searched in both isolation and through the use of Boolean strategies.  
 The database search yielded hundreds of relevant primary research articles for potential 
inclusion in this literature review. Inclusion criteria included those that involved primary 
research, were published in 2016 or later, and had direct relevance to the current dissertation. 
Initial screening included title review followed by abstract review for potentially relevant 
articles. Those that offered the most relevant information were then selected for complete 
analysis and inclusion. The following represents a current perspective of this subject matter as it 
relates to the use of telehealth in reducing costs, readmissions, and exacerbations of patients 
recently discharged for CHF and COPD conditions.  
Overview of the CHF Healthcare Burdens 
 In terms of CHF, this condition affects a significant number of individuals worldwide. 
Somewhere between one and two percent of all individuals across the globe suffer from this 
condition (Tung et al., 2016). The U.S. shares 28 percent of the global HF burden, and Europe is 
responsible for 7 percent of the global HF costs (Lesyuk, Kriza, & Kolominsky-Rabas, 2018). 
Likewise, CHF is the most common cause of patient readmissions after a 30-day discharge from 
the hospital. This is particularly noteworthy since 76 percent of these readmissions are 
considered to be preventable in nature (Chamberlain et al., 2018). Based on these figures, 




care strategies for this population would make a significantly favorable impact on healthcare 
outcomes overall (Bergethon et al., 2016).  
 Part of the rising concern regarding the CHF burden in the U.S. involves the aging of the 
population. Based on recent assessments, over 80 percent of those hospitalized with CHF are 
over 65 years of age. Likewise, roughly 90 percent of CHF deaths occur in this age group 
(Lesyuk, Kriza & Kolominsky-Rabas, 2018). In addition, this segment of the population is 
expanding rapidly due to generational fluctuations and improved longevity. Estimates suggest 
that these population shifts will increase the number of CHF patients over 8 million by the year 
2030 (Zohrabian, Kapp & Simoes, 2018). For example, less than two percent of all people have 
CHF; but, a tenth of those over the age of 70 years suffer from the condition (Tung et al., 2016). 
Given these trends, it is evident that CHF will impose even greater burdens on U.S. healthcare 
systems unless notable changes are made.  
 While the CHF’s primary burden involves health effects, quality of life, and mortality 
rates, healthcare costs are also major considerations related to CHF care in the U.S. In 2012, the 
American Heart Association noted the total cost of managing CHF was $21 billion. However, by 
2030, they predict these costs will have increased to $53 billion (Chamberlain et al., 2018). 
Others have indicated that CHF care costs will be as high as $69.7 billion by 2030 (Zohrabian, 
Kapp & Simoes, 2018). Of these costs, roughly two-thirds are due to direct costs related to 
provider care (Bergethon et al., 2016; Lesyuk, Kriza, & Kolominsky-Rabas, 2018). The 
remaining costs are those that are indirect related to impaired functional abilities and ability to 
work (Lesyuk, Kriza, & Kolominsky-Rabas, 2018).  
 In terms of specific costs, the U.S. is a leader in healthcare expenditures for CHF care. In 




patient-related to CHF care (Lesyuk, Kriza & Kolominsky-Rabas, 2018). On average, the U.S. 
spends between $22,000 and $25,000 per patient with CHF, with overall lifetime costs per 
patient being nearly $127,000 (Lesyuk, Kriza & Kolominsky-Rabas, 2018). Other researchers 
have noted that CHF care represents the sixth most expensive treatment in the U.S. (Zohrabian, 
Kapp & Simoes, 2018). Of these costs, hospitalization tends to represent more than half of all 
CHF expenditures (Tung et al., 2016). All of this data explains why CHF represents a significant 
burden on the U.S. healthcare system. 
CHF and Hospital Admissions  
In patients with CHF, hospital admission rates are notably elevated. Research has 
demonstrated that these admissions are not only frequent but likewise extended and costly. In a 
retrospective, observational study performed by Kilgore and colleagues (2017), they examined a 
variety of metrics from a large Medicare cohort with CHF between 2005 and 2011. In total, 
nearly 64,000 patients were included in the analysis, and the overall rate of hospitalization was 
218.8 admissions for every 100 person-years (Kilgore et al., 2017). Furthermore, the average 
length of stay for these admissions was five days, and the average cost for each hospitalization 
was $14,631 (Kilgore et al., 2017). These findings quickly highlight the magnitude of the 
problem relating to CHF and hospital admissions.  
 As might be expected, the rate of hospitalization increases in the last year of life for 
patients with CHF. Interestingly, the cause of these hospitalizations is not always directly related 
to CHF declines. In a retrospective study by Madelaire and coworkers (2019), nationwide Danish 
registries were used to determine the frequency and cause of hospitalization in the last year of 
life with individuals suffering from CHF. The frequency of hospitalizations was relatively high, 




average number of hospitalizations was two per year (Madelaire et al., 2019). But of these 
hospitalizations, a total of 64 percent were unrelated to CHF or even cardiovascular causes 
(Madelaire et al., 2019). This would imply that comorbid conditions play a notable role in 
hospital admissions for CHF patients.  
 Several studies have examined which comorbidities pose the greatest risk for CHF 
patients in terms of hospital admissions. Poffo and researchers (2017) performed a cross-
sectional, retrospective study of 816 CHF patients and found several factors that increased their 
risk of hospitalization. These included not only cardiovascular disease but also renal failure, 
pulmonary embolism, and pulmonary infections (Poffo et al., 2017). Wu and colleagues (2019) 
examined 482 patients with CHF exacerbations and noted that poor medication adherence was 
the most common trigger for the hospital admission. Likewise, they also found that depression, 
hypertension, recent medication changes, and renal failure were other risks that made 
hospitalization more likely (Wu et al., 2019).  
 Hospital admissions are thus common among CHF patients, create a significant economic 
burden, and are often associated with additional health behaviors and factors besides CHF. While 
CHF management is important, a broader perspective is needed to reduce CHF admissions 
(Madelaire et al., 2019). By 2030, it is expected that 8.5 million in the U.S. will have CHF, and 
the mortality rate for this population is roughly 50 percent within five years (Kilgore et al., 
2017). Likewise, the economic impact of this is in the billions (Kilgore et al., 2017). All of this 
supports the need to identify better ways of CHF care. 
CHF and Hospital Readmissions 
 One of the most notable concerns regarding CHF burden and costs involve hospital 




discharged from a hospitalization. While this can be assessed based on 15 days or 90 days after 
discharge, most criteria adopt a 30-day cutoff for readmission for data analysis purposes 
(Zohrabian, Kapp & Simoes, 2018). Based on this, it has been noted that approximately a quarter 
of all CHF patients recently discharged are readmitted within 30 days (Tung et al., 2016). This is 
important because of the frequency with which CHF patients are hospitalized. Of all CHF 
patients, researchers note that 83 percent will be hospitalized at least once. More importantly, 
nearly half of these patients will be admitted four or more times for CHF (Zohrabian, Kapp & 
Simoes, 2018). Based on this data, a reduction in readmission rates could have tremendous 
effects in reducing costs of care.  
 Readmission within 30 days for CHF patients has been shown to correlate with a poor 
prognosis over time. Those who fall into this category have been noted to have a mortality rate 
between five and fifteen percent at 90 days post-discharge (Tung et al., 2016). In addition, 
readmissions for CHF are costly in nature. In a study examining such costs, 15-day readmissions 
for CHF were estimated to cost $600 million (Chamberlain et al., 2018). To put this in volume 
perspective, there are over 1 million CHF hospitalizations per year, and a quarter of these are 
readmissions within 30 days of discharge. With three-quarters of these being preventable, the 
potential for reduced admissions would approach 175,000 CHF hospital admissions per year 
(Chamberlain et al., 2018).  
 One approach toward reducing CHF readmissions and costs is identifying those at the 
highest risk for readmission. Chamberlain and colleagues (2018) conducted a study to assess 
various risks to stratify CHF patients into low, intermediate, and high-risk groups. In examining 
such risks, they identified 12 variables that deserved attention. These include age over 65 years; 




Medicaid or lack of health insurance; drug use; renal failure; COPD; diabetes; depression; and 
electrolyte disturbances (Chamberlain et al., 2018). CHF patients with a higher number of these 
conditions or behaviors are most likely to be readmitted, which offers insights about how 
prevention might be pursued (Chamberlain et al., 2018).  
 To date, the ability of hospitals to reduce CHF readmission rates has been limited at best. 
Prior to implementing the HRRP by the Centers for Medicare and Medicaid Services (CMS), 
hospital CHF management programs at discharge only reduced 30-day readmission rates by one 
percent (Bergethon et al., 2016). Likewise, HRRP incentives have fallen well short of targeted 
readmission rate reductions, with research suggesting drops have been less than 40 percent of 
what was predicted (Gupta & Fonarow, 2018). Understanding this, it is evident that solutions to 
CHF readmissions are still needed, and based on volume and cost data, this need is significant.  
Overview of the COPD Healthcare Burden 
 In terms of COPD, this pulmonary condition is also quite prevalent within the U.S. and is 
associated with significant healthcare expenditures as well. Some researchers have suggested that 
15.7 million individuals suffer from COPD in the U.S. (Stammer, 2018). Others have tallied the 
figure at a higher level, up to 24 million representing 7.5 percent of the U.S. population (Rezaee 
et al., 2018). In either case, COPD is common, and it is noted to be the third leading cause of 
death in the country (Stammer, 2018). While mortality rates with those with COPD are high, 
exacerbations and presentations to emergency rooms and hospitals are high as well. On average, 
roughly 77 percent of all patients with COPD have at least one exacerbation each year requiring 
medical care (Stammer, 2018).  
 Like CHF healthcare expenditures, costs related to COPD are on the rise as well. In 2010, 




to $49 billion within a decade (Stammer, 2018). This increase is due to an increased prevalence 
of cases combined with an aging population. A higher percentage of the population is over age 
65 years, and many suffer from one or more chronic diseases like COPD (Liu, Xiang, Lagor, Liu 
& Sullivan, 2016). At the same time, costs of care have also increased while the number of 
COPD exacerbations per patient has not. This also has contributed to rising costs related to this 
condition (Vasilopoulou et al., 2017).  
 A significant amount of research data exists that offers insights about the specific costs 
related to COPD care. International studies have suggested that the main cost of care for a single 
COPD exacerbation is roughly $2,000. Understanding that a COPD patient on average has 1.7 
exacerbations annually, this would suggest annual costs to be around $3,400 per patient per year 
(Vasilopoulou et al., 2017). These figures are similar to U.S. studies reporting 2010 cost figures 
for COPD care. In 2010, nearly $50 billion was spent on COPD care throughout the nation, 
which equated to roughly $4,000 per patient that year (Rezaee et al., 2018). When averaged 
across all COPD patients, this appears to be a relatively consistent cost figure.  
 In considering the cost burden of COPD care, it is important to recognize that disparity 
exists among COPD care levels. Though costs can be averaged among all patients and 
determined to be between $3,400 and $4,000 per patient annually, high costs are experienced by 
those who suffer exacerbations (Rezaee et al., 2018). Given that more than two-thirds of COPD 
patients have annual exacerbations, costs for this segment of the COPD patient population are 
warranted. For these individuals, it has been estimated that the average cost per exacerbation 
occurrence exceeds $7,000 (Stammer, 2018). Thus, COPD patients who fall into this category 




would therefore make logical sense from a cost perspective as well as a care perspective 
(Stammer, 2018).  
COPD Exacerbations and Emergency Department Visits 
 COPD exacerbations are common in the U.S. and worldwide. Different studies, however, 
suggest different rates of occurrence of COPD exacerbations account for 30-day readmissions 
and ED visits. Stammer (2018) states that 23 percent of those with COPD exacerbations are 
readmitted within 30 days of discharge. Likewise, Kargiannakis and coworkers (2017) note that 
the average readmission rate within 28-days for COPD patient discharges is 20 percent. Rezaee 
and colleagues (2018) break this figure down based on primary and all-cause readmissions. 
Those requiring readmission within 30 days due to a primary COPD exacerbation have a 
readmission rate of 7.1 percent. But COPD patients being admitted for any cause within 30 days 
have a readmission rate of 20.5 percent (Rezaee et al., 2018). In either case, a reduction in 30-
day readmissions is preferable given the expense of these readmissions.  
 It is notable that a key part of preventing readmission of COPD patients involves 
avoiding ED visits for exacerbations if possible. In a retrospective analysis, roughly 82 percent 
of all COPD 30-day readmission occur via the ED (Rezaee et al., 2018). Other interventional 
studies among COPD patients performed by Farias and colleagues (2018) also show high ED 
visits among those being readmitted with COPD. Out of 256 enrolled COPD patients, baseline 
data showed that 120 presented to the ED with respiratory complaints during the study. This is 
roughly half of all the COPD patients who were followed (Farias et al., 2018). Likewise, a total 
of 75 patients were then admitted to the hospital from this group, which represents around 60 
percent of all COPD presenting to the ED (Farias et al., 2018). This data supports the notion that 




 In considering strategies to reduce the ED presentations of COPD patients after recent 
discharge, it is important to assess key risk factors for this potential population. Research is 
helpful in this regard. Rezaee and researchers (2018) have noted some statistics regarding COPD 
readmissions and ED presentations. Specifically, more than half of this group present with 
primary breathing difficulties, and a total of 16 percent are readmitted within 48 hours of 
discharge (Rezaee et al., 2018). Likewise, albuterol use, tobacco use, and an increase in pulse 
also identify higher risk COPD patients for exacerbations and readmission (Rezaee et al., 2018). 
Other noted changes that might be detected to indicate higher risk include pulse oximeter 
changes, blood pressure changes, and other non-respiratory complaints such as increasing fatigue 
and difficulties with self-care (Kargiannakis, Fitzsimmons, Bentley, & Mountain, 2017; 
Stammer, 2018). These provide insights about COPD patients who may be most like to have an 
exacerbation and represent to the ED for readmission.  
 Efforts to reduce ED visits among COPD patients have been pursued over the years, and 
insights from these efforts have been gained. Sanchez-Nieto and coworkers (2016) conducted an 
extensive multicenter randomized controlled trial that followed severe COPD patients for a year. 
Half received interventions that include education, inhaler training, a written action plan for 
activities, and treatment instructions for stable and acute needs (Sanchez-Nieto et al., 2016). 
These interventions reduced ED visits and exacerbations by a third over the course of a year 
(Sanchez-Nieto et al., 2016). Other studies have supported the benefit of written action plans as 
well. Farias and colleagues (2018) found that such plans could prevent 40 percent of COPD 
hospitalizations. However, the adherence rate to these plans was less than 50 percent, showing 




key targets for reducing COPD ED visits and readmissions involve a multicomponent approach, 
patient engagement, and risk identification (Sanchez-Nieto et al., 2016). 
COPD Exacerbations and Admissions 
In addition to ED visits, COPD patients pose notable costs to healthcare as a result of 
hospitalizations as well. In fact, COPD patient hospitalization figures approach ED visit figures 
in many areas. Gershon and colleagues (2017) explored this issue by performing a time series 
data analysis in Ontario using government healthcare databases. Between 2003 and 2014, the 
percentage of the population with COPD increased from 8.9 percent to 11.1 percent. This 
resulted in 290,482 ED visits for the time period reviewed, but it also resulted in 274,951 
hospitalizations as well (Gershon, et al., 2017). Based on this data, the researchers concluded that 
the hospitalization rate for those with COPD was 2.7 occurrences for every 1,000 people with 
COPD each year (Gershon, et al., 2017).  
 Like CHF, hospital admissions for COPD patients drive healthcare costs up substantially. 
Systematic reviews evaluating these costs have found that for every COPD patient in the U.S., 
annual costs related to hospitalization average $6,852 (Rehman et al., 2020). In addition, several 
objective predictors identify which COPD patients are at the highest risk for hospital admissions. 
Naz and coworkers (2017) compared COPD patients and their presentation for admission based 
on their exercise performance capacities. Their findings showed that COPD patients who 
perform poorly on walking tests, dyspnea scales, arterial blood gases, and other pulmonary 
function tests are much more likely to be admitted to a hospital (Naz, Sahin, Karasu, & Aksel, 
2017).  
 Understanding this, incentives exist to reduce not only ED visits for COPD patients but 




estimates suggesting 12.4 percent of the population in 2024 will be affected with this condition 
(Gershon, et al., 2017). While the overall hospital admission rate has held steady in past decades, 
the increase in volume of percent populations with COPD still mean total hospitalization 
numbers will likely increase (Gershon, et al., 2017). Likewise, reduced costs related to hospital 
admissions for COPD patients are not expected (ur Rehman, et al., 2020). Therefore, methods to 
identify COPD conditions early and introduce better proactive and preventative measures to 
deter exacerbations are imperative. 
Overview of the Hospital Readmission Reduction Program 
 Understanding a sizable portion of GDP goes toward healthcare expenditures, efforts 
have been pursued to provide incentives for hospitals and providers to reduce costs while still 
rendering high-quality care. Over the course of several decades, government and private insurers 
have moved away from a fee-for-service model to one where reimbursement is based on 
diagnoses and diagnosis-related groups (DRGs) (Bergethon et al., 2016). This similarly failed to 
control healthcare costs, and as a result, CMS introduced programs that penalized hospitals for 
overutilization of services. Specifically, this was initially introduced as the Hospital Readmission 
Reduction Program in 2010 as part of the Affordable Care Act (Zohrabian, Kapp & Simoes, 
2018).  
 The premise of the HRRP was that hospitals should be incentivized to avoid 30-day 
readmissions for some conditions. The initial conditions CMS chose as targets included CHF, 
acute myocardial infarction, and pneumonia (Zohrabian, Kapp, & Simoes, 2018). However, this 
was soon expanded to include other conditions include early readmissions for COPD 
exacerbations (Stammer, 2018). In essence, should a hospital exceed 30-day readmission targets, 




penalties were initially one percent during the first year of HRRP in 2013. This then increased to 
three percent by 2015 (Chamberlain et al., 2018). The financial setbacks were believed to be 
enough to encourage hospitals to adopt practices that reduced 30-day readmissions substantially 
(Gupta & Fonarow, 2018).  
 Unfortunately, hospitals have since struggled with embracing new approaches to avoid 
CMS penalties under the HRRP. According to Gupta and Fonarow (2018), approximately 79 
percent of all hospitals were penalized for readmission rates that exceeded targets. This 
accounted for a total of $528 million of Medicare payments withheld (Gupta & Fonarow, 2018). 
This figure then climbed to $564 million in 2018 according to research conducted by Zohrabian 
and colleagues (2018). The reductions in readmission rates fell well short of CMS’ targets. For 
CHF, CMS hoped the HRRP would reduce 30-day readmissions by 25 percent. However, in 
actuality, only a nine percent reduction was realized (Gupta & Fonarow, 2018). This 
demonstrates the ineffectiveness of this program to achieve intended success.  
 One of the biggest concerns regarding the HRRP from its onset was the ability to hold 
hospitals accountable. While incentives were created to deter poor healthcare practices so that 
early readmissions could be avoided, some chose to game the system instead (Gupta & Fonarow, 
2018). Gaming the system can be accomplished in a variety of ways. Some hospitals participate 
in administrative upcoding so that an admission is not considered a readmission. Others will 
extend the number of observation days in an effort to avoid the 30-day cutoff (Gupta & Fonarow, 
2018). More concerning are practices that actually undermine patient care. These include 
purposeful delays for readmission past a 30-day target and inappropriate ED triage procedures 
(Gupta & Fonarow, 2018). For some hospitals, these strategies were easier to employ when 




 Indeed, some reduction in readmission rates has been achieved with the HRRP. However, 
these have come at a cost. For example, mortality rates related to CHF had been declining 
annually for decades. But since the implementation of HRRP, CHF mortality rates have been 
noted to be higher at 30-day, 90-day, and 1-year time periods (Gupta & Fonarow, 2018). In 
essence, the HRRP created a moral hazard for some providers where their best option was to 
game the system to reduce costly penalties. But in the process, patient outcomes declined, and 
mortality rates rose for conditions like CHF (Zohrabian, Kapp & Simoes, 2018). From this 
perspective, HRRP may have reduced some costs related to readmission, but the overall goals of 
enhanced healthcare have not been achieved (Zohrabian, Kapp & Simoes, 2018).  
Gupta and colleagues (2018) performed a study to explore the relationship of the HRRP 
with readmission and mortality consequences among patients admitted to hospitals with heart 
failure. They observed that the mortality rate for HF patients increased within the 30-day and 1-
year after the implementation of the HRRP. With the HRRP implementation, the 30-day 
mortality for HF patients raised from 7.9 percent in 2008 to 9.2 percent in 2014, a 1.3 percent 
total increase (Gupta et al., 2018). From this perspective, HRRP may have reduced some costs 
related to readmission, but the overall goals of enhanced healthcare have not been achieved 
(Zohrabian, Kapp & Simoes, 2018).  
 The HRRP can be seen as having many shortcomings that have accounted for its limited 
success. Based on data from the last several years, HRRP commonly imposes persistent penalties 
on hospitals even when efforts to reduce readmissions are valid and evidence-based in nature. As 
a result, hospitals feel they have a limited capacity to avoid penalties or to control outcomes 
(Zohrabian, Kapp & Simoes, 2018). Based on collected data, penalties range from hundreds of 




are unpredictable, other opportunities to reclaim these losses must be considered. For many 
hospitals, this means invested resources in more lucrative areas and accepting the fact they will 
lose HRRP penalties (Zohrabian, Kapp, & Simoes, 2018).  
 In some respects, the HRRP has been ineffective in reducing the utilization of resources 
and deterring readmission rates. Costs remain high, as does readmission rates for several 
conditions, including CHF and COPD (Gupta & Fonarow, 2018; Stammer, 2018). The reason for 
this has not only been challenged in predicting penalties and avoiding them. The HRRP also fails 
to address quality of care, patient safety, and patient outcomes in its formulations (Gupta & 
Fonarow, 2018). For this reason, new models are being pursued by CMS including those related 
to bundled payment programs, patient-centered medical homes, and accountable care 
organizations (Gupta & Fonarow, 2018). Cost remains a part of these incentives, but they expand 
their approach to include quality of care aspects as well (Gupta & Fonarow, 2018).  
Telehealth Programs and Cost Reduction Potential  
 Over the last several decades, telehealth systems have advanced tremendously within 
healthcare systems. These systems are defined as involving the use of video, electronic, and 
other telecommunications information to monitor patients and transmit data regarding patients’ 
health at a distance (Liu et al., 2016). Overall, telehealth offers many potential advantages. For 
some patients, especially those in rural areas, healthcare access can be greatly improved. 
Likewise, access to a limited number of specialists can also be improved through telehealth 
systems (Snoswell et al., 2020). At the same time, telehealth systems can also improve resource 
use efficiency, and provider productivity (Snoswell et al., 2020).  
 While these are important drivers of telehealth use, cost savings have been recognized as 




form of travel time and expenses as well as in relation to provider wait times (Snoswell et al., 
2020). Likewise, telehealth services are being increasingly used for remote patient monitoring to 
reduce in-person visits, disease exacerbations, and unnecessary readmissions (Deasfernandes, 
2020). Telehealth can offer biometric surveillance data that might alert providers to needed 
interventions, and likewise, it can also facilitate care collaboration that reduces potential costly 
setbacks (Deasfernandes, 2020).  
 In regard to cost reduction potential, telehealth can also empower patients to become 
more engaged and involved in their own care. Enhanced self-care management has been well 
recognized as a benefit of telehealth systems in some conditions (Kargiannakis et al., 2017). 
Self-efficacy models exploring telehealth in patients with chronic illness note that patients 
routinely participate more actively in their care in such settings, which in turn improves 
adherence rates to care instructions (Stammer, 2018). Naturally, this has the potential to reduce 
care costs by reducing ED visits, hospitalizations, and disease exacerbations; however, it also 
improves the quality of life and patient outcomes as well (Stammer, 2018).  
 Numerous analyses regarding the cost-effectiveness of telehealth have been performed, 
and expert focus groups have convened to provide their own assessments in this regard. Notably, 
the group recognized that cost savings would result in situations where travel costs were 
extensive or when a costly procedure or specialist care was avoided (Snoswell et al., 2020). 
However, they also noted that cost savings could result from productivity gains, reduced 
secondary care, and telementoring efforts (Snoswell et al., 2020). In their assessment, however, 
tele-mentoring was believed to have a small impact on costs compared to productivity gains and 
reduced secondary care. Likewise, the cost savings in the other areas were believed to be small 




 While the expert panel examined telehealth in a broad sense in its ability to reduce costs, 
other studies have provided a more focused assessment. Liu and colleagues (2016) performed a 
more comprehensive assessment of cost savings of telehealth by examining the same aspects of 
telehealth expenses. However, they evaluated cost reductions based on patient severity, average 
hospitalization cost, and overall length of stay. Based on their analysis, it was evident that 
telehealth programs offered significant cost savings for some populations and situations and not 
others (Liu et al., 2016). Thus, a blanket statement regarding the cost savings potential of 
telehealth services cannot be made for all scenarios. Instead, they must be assessed for the 
specific condition and patient environment being considered (Liu et al., 2016). 
Telehealth Programs to Reduce CHF Admissions 
Examinations of telehealth programs in CHF have been performed related to hospital 
admissions and other variables. Lin and colleagues (2016) conducted a large systematic review 
and meta-analysis that involved 39 randomized controlled trials where telehealth was utilized for 
CHF patients. The outcomes that were measured in their analysis included all-cause admission 
rates, CHF-related admission rates, CHF-related admission length of stay, and CHF-related 
mortality (Lin et al., 2016). In the trial, either tele-transmission or telephonic interventions were 
compared to standard of care. In their summaries, the researchers found that telehealth using tele-
transmission improved all measures they assessed to a statistically significant degree. Likewise, 
telephonic telehealth was also notable significant in reducing CHF-related admissions (Lin et al., 
2016). Given this study's quality and magnitude, strong support for telehealth use in deterring 
CHF hospital admissions is found.  
 While this evidence suggests reduced hospital admission rates and lengths of stays for 




for this population. Burdese and coworkers (2018) evaluated the efficacy, costs, and patient 
acceptance level among CHF patients receiving telehealth services. The study took place over 20 
months, where high-risk CHF patients were followed over time. A total of 48 CHF participants 
were included (Burdese et al., 2018). In a pre-intervention/post-intervention format, the 
researchers found hospital admission rates dropped from 35 each year to 12 each year once 
telehealth was implemented. They also found that costs in Euros fell from €116,856 for the entire 
year previously to €40,065 afterward (Burdese et al., 2018). 
 In the research, some have questioned whether the pursuit of telehealth in reducing CHF 
hospital admissions is worthwhile. The arguments have been that implementing multidisciplinary 
teams and telehealth systems increase costs beyond the potential admission reductions that might 
follow (Blood, Fraiche & Eapen, 2017). However, quality research supports that this is not the 
case. Studies identify that hospital admissions significantly improve CHF patients’ quality of life 
and disease severity (Lin et al., 2016). Likewise, these telehealth services can be implemented at 
a reasonable cost and save healthcare systems significantly (Burdese et al., 2018). 
Telehealth Programs to Reduce CHF Readmissions 
 Understanding that telehealth services may reduce costs only in specific instances, it is 
important to assess its use in CHF. This is particularly important in relation to telehealth 
programs’ ability to reduce CHF hospital readmissions within 30 days since this would greatly 
impact hospital CMS penalties under the HRRP (Zohrabian, Kapp & Simoes, 2018). In theory, 
telehealth could offer education, monitoring, and remote interventions that could deter premature 
readmissions in this patient population, and at the same time, promote greater self-management 




 In this regard, Deasfernandes (2020) performed a quantitative study to examine these 
issues in CHF patients. A total of 110 CHF patients who had been recently discharged were 
enrolled in a program where telehealth services were provided. These services included patient-
centered virtual visits, daily biometric surveillance, and improved patient and provider access to 
patient information (Deasfernandes, 2020). Upon post-intervention assessments compared to 
preintervention data, the telehealth program significantly reduced hospital readmission rates. At 
the same time, it also improved patients’ self-management skills and boosted care coordination 
among the care team (Deasfernandes, 2020). The author concluded that the telehealth program 
had the potential for yielded both cost savings as well as improved CHF care, but it was also 
noted that additional studies were needed (Deasfernandes, 2020).  
 Notable in the aforementioned research was the lack of expense data related to the 
telehealth program implemented for the CHF patients (Deasfernandes, 2020). However, other 
research has performed more extensive analyses in this regard by developing a Markov Model 
that more objectively predicts whether such a program might result in cost savings or losses (Liu 
et al., 2016). In short, a Markov Model is a state transition model that is used in assessing the 
cost-effectiveness of new interventions. Not only does such a model explore cost savings, but it 
also defines upfront and ongoing expenditures that could undermine cost-effectiveness over time 
(Liu et al., 2016).  
 In the research study, Liu and colleagues (2016) considered a number of costs related to a 
telehealth program. These included install and uninstall costs of the technology, monitoring 
costs, nursing resources, and input and output costs of enrolling patients. Expert estimations and 
research provided the sources of these cost determinations for the model. As a result, installation 




costs $125 per month (Liu et al., 2016). At the same time, usual care costs for CHF patients were 
also estimated for comparison. This included a CHF hospitalization cost of $12,000, annual 
outpatient visit costs of $1,700, and other annual non-CHF costs of $10,000 (Liu et al.,2016). 
These were then extrapolated based on CHF severity over a 5-year period of time (Liu et al., 
2016).  
 In the final assessment of the cost-effectiveness of a telehealth program for CHF patients, 
the researchers noted patient severity had the greatest impact. For CHF patients with low-level 
severity CHF, the program actually increased costs per patient by $2,502 per year. In contrast, 
however, cost savings were noted for intermediate-level severity and high-level severity CHF 
patients with the telehealth program, which were $2,832 and $5,499 per year, respectively (Liu et 
al., 2016). In short, telehealth services reduced healthcare costs and the number of hospital 
admissions for intermediate-level and high-level severity CHF patients while also slightly 
improving their overall life expectancy (Liu et al., 2016).  
 Based on this data, it suggests that telehealth programs offer cost-savings for some CHF 
patients while reducing readmission rates as well (Liu et al., 2016). This appears to be achieved 
through a variety of mechanisms that include better self-management skills, enhanced patient 
engagement, improved access to information, and improved overall provider and patient 
education (Deasfernandes, 2020; Liu et al., 2016). While telehealth may not be cost-effective as 
a broad service implementation for CHF patients, it does appear to have a potential role in some 
instances (Liu et al., 2016). This is highly relevant in the pursuit of reducing 30-day readmission 






Telehealth Programs to Reduce COPD Exacerbations 
 In comparing the literature regarding telehealth programs to reduce CHF readmission 
versus those to reduce COPD exacerbations, several studies have explored telehealth programs 
among COPD patients. Many of these embrace a self-management theoretical perspective and 
support the notion that telehealth enhances these abilities (Farias et al., 2018; Kargiannakis et al., 
2017; Sanchez-Nieto et al., 2016; and Stammer, 2018). By using telehealth to implement and 
oversee a proactive action plan of care for COPD, it is believed self-management increases while 
COPD exacerbations and readmissions decrease (Kargiannakis et al., 2017).  
 Improvements in self-management abilities among COPD patients have been evaluated in 
terms of their efficacy. Sanchez-Nieto and coworkers (2016) conducted a multicenter, 
randomized controlled trial for this purpose involving 85 COPD patients at two different hospital 
sites. Interventions, which were received by 47 participants, included group education, inhalation 
technique training, physical written action planning, and defined treatments for maintenance and 
exacerbation phases (Sanchez-Nieto et al., 2016). Over the course of a year, ED visits for COPD 
exacerbations and COPD-related hospitalizations dropped from 1.37 per patient to 0.89 per 
patient, which was statistically significant (Sanchez-Nieto et al., 2016). The researchers stated 
that the results support the benefits of interventions that enhance self-management abilities 
among COPD patients (Sanchez-Nieto et al., 2016).  
 One of these investigations involved a pilot study that involved 23 patients with known 
COPD. Kargiannakis and coworkers (2017) implemented a community-based telehealth program 
for COPD patients recently discharged from the hospital. The telehealth system captured manual 
data, clinical record data, and biometric data, and providers and managers were alerted when 




problems, and out-of-range blood pressure readings (Kargiannakis et al., 2017). The intervention 
was for eight weeks with 6-months of monitoring overall. The results showed that readmission 
rates fell to nine percent from a baseline average of 20 percent prior to telehealth program use 
(Kargiannakis et al., 2017).  
 Another small study performed by Stammer (2018) involving telehealth use in recently 
discharged COPD patients was conducted using a self-efficacy model as well. Readmission rates 
for COPD patients within 30 days were examined by capturing pre-and post-intervention data. 
The intervention consisted of a telehealth monitoring system that followed pulse oximetry, heart 
rate, blood pressure as well as subjective reports of symptoms (Stammer, 2018). The results of 
the study showed a 27 percent reduction in readmission rates within 30 days for COPD patients, 
falling from 38 percent to 11 percent. Though the sample size was small and only involved eight 
patients prior and nine patients after the telehealth system, the findings were believed to be 
substantial (Stammer, 2018).  
 Larger studies have also been employed using telehealth in a COPD patient population. 
Farias and colleagues (2018) conducted a pre-and post-intervention trial involving 256 COPD 
patients in an outpatient setting. The intervention consisted of an interactive telehealth system 
that used a written action plan to monitor patient adherence (Farias et al., 2018). Prior to the 
intervention, COPD patients were given the same written action plan, but adherence rates were 
less than 50 percent. Likewise, a total of 75 of the participants were hospitalized, and 120 seen in 
the ED for respiratory complaints (Farias et al., 2018). After the telehealth intervention, 
adherence improved to 72 percent, hospitalizations fell to 65, and ED visits for exacerbations 
dropped to 110 (Farias et al., 2018). Though the degree of improvement was small, the changes 




 While several research studies have examined the use of telehealth to reduce COPD 
exacerbations, ED visits, and readmissions, few have mentioned cost-effectiveness. Sanchez-
Nieto and coworkers (2016) in their study, however, specifically noted that this was needed. 
However, one study conducted by Vasilopoulou and colleagues (2017) did explore this issue to a 
degree. In their study, they implemented a home-based telehealth rehabilitation program as part 
of a prospective, randomized controlled trial. A total of 147 COPD patients were divided into 
three groups. One group received 12 months of telehealth pulmonary rehabilitation, one group 
received outpatient pulmonary rehabilitation, and the third group received usual COPD care 
without pulmonary rehabilitation (Vasilopoulou et al., 2017). The researchers found that while 
the telehealth pulmonary rehabilitation reduced COPD exacerbations and hospitalizations equal 
to the outpatient rehabilitation group, the telehealth group had the fewest ED visits overall 
(Vasilopoulou et al., 2017).  
 In evaluating their results in relation to costs, Vasilopoulou and colleagues (2017) 
compared the mean cost for a COPD exacerbation in Greece, which was determined to be $2,000 
per patient encounter. It was then estimated that the overall cost of the telehealth system based 
on a per-patient use was roughly $2,100. Given that the average number of exacerbations per 
COPD patient in Greece was 1.7 per year, the researchers calculated that the nation would spend 
40 percent less on healthcare expenditures by implementing such a telehealth system 
(Vasilopoulou et al., 2017). Thus, the cost advantages further supported the clinical benefits that 
the telehealth system offered for this patient group.  
Telehealth Programs to Reduce COPD Admissions 
In addition to examining COPD exacerbations and telehealth use, some research has 




Bandurska and researchers (2019) explored this from a conceptual perspective by employing an 
integrated care model that offered ongoing home-oriented support. A total of 44 COPD patients 
were enrolled in the program that involved the use of a multidisciplinary team. Over the course 
of six months, the researchers evaluated not only ambulatory care visits and ED visits but also 
hospitalizations (Bandurska et al., 2019). They noted that hospital admissions using this model 
were highly effective, resulting in a statistically significant decline. They also found that costs 
related to COPD hospital admissions fell by €312 per patient on average (Bandurska, et al., 
2019). 
 Another study examined a variety of self-management interventions for COPD patients 
that included telehealth services. In a systematic review of 26 randomized controlled trials, 
Newham and colleagues (2017) evaluated benefits for COPD patients related to the quality of 
life and hospital presentations. They noted that these types of interventions significantly 
improved quality of life and reduced COPD severity, and they also found fewer hospital 
presentations (Newham et al., 2017). However, they found that more severe COPD patients 
benefitted from these services more, and single providers often performed better than 
multidisciplinary teams based on their review (Newham et al., 2019). They also found that 
benefits correlated well with the number of self-management sessions performed (Newham et al., 
2019).  
 As an overview of the use of telehealth systems to reduce COPD exacerbations, ED 
visits, and hospital readmissions, the research evidence is generally supportive (Farias et al., 
2018; Sanchez-Nieto et al., 2016). Likewise, limited research has suggested cost benefits 
(Vasilopoulou et al., 2017). The mechanism by which these programs offer benefits appear to be 




self-management skills, and general oversight abilities (Stammer, 2018). However, research has 
yet to define specific subsets of COPD patients or particular situations where these programs 
might be the most useful.  
Conclusion 
 Based on current literature research, both CHF and COPD represent common health 
conditions that impose notable costs on healthcare systems. Patients with CHF reflect those who 
are most commonly readmitted to the hospital within a 30-day period, and individuals with 
COPD burden emergency rooms often with exacerbations that could be prevented through more 
effective care. They also account for large numbers of hospital admissions each year that 
similarly result in significant economic burdens. Understandably, better strategies are needed to 
address these common conditions and their related effects. 
Efforts to reduce expenditures related to CHF admissions and readmissions  as well as 
COPD exacerbations  and admissions have been pursued through various measures. These have 
included efforts to identify risk factors, improvement in management techniques, and in early 
diagnosis efforts. These have also involve programs like the Hospital Readmission Reduction 
Program, written action plans, patient education, and strategies to enhance patient self-
management. However, these efforts have failed in most cases to fully address the problem and 
reduce costs related to these conditions. Though some strategies have showed some success, 
research suggests patient outcomes may actually be worse as a result of these efforts. 
 Telehealth systems offer potential advantages for addressing these issues through 
a variety of measures. Telehealth research supports its ability to improve access to care and 
information in a variety of clinical situations, and it also has the potential to improve productivity 




and COPD patient care. For CHF, evidence supports it reduces hospital admissions and 
readmissions, and it is also cost-effective when applied to CHF patients with more advanced 
severity of illness.  
Evidence also supports telehealth’s role in reducing COPD exacerbation, ED visits, and 
hospitalizations through enhanced oversight and self-management. Various self-management 
interventions and integrated care models combined with telehealth practices show promise in 
better managing COPD and reducing exacerbations and admissions. Some evidence also shows it 
too may be cost-effective for COPD patients as well in this regard. Thus, in summary, current 
literature supports further exploration of the use of telehealth in its ability to reduce costs related 

















CHAPTER III – METHODS 
The primary purpose of the current study is to evaluate the existing healthcare costs that 
healthcare emergency departments (EDs) and hospitals incur as a result of ED visits from 
exacerbations of chronic obstructive pulmonary disease (COPD) and hospital admissions for 
congestive heart failure (CHF) within the state of Florida in 2018. These data insights can be 
used to better determine where healthcare resources might be used, specifically telehealth 
services, to achieve the greater impact. With this in mind, the following details explain the 
specific methodologies that will be used in performing this evaluation.  
Study Design and Setting 
 The study design chosen will be a retrospective cohort study analysis of HCUP archival 
billing data that examines specific databases relevant to the concepts identified. Two specific 
databases will be accessed that provide information about state costs related to ED visits for 
COPD exacerbations and hospital admissions for CHF. Both databases are maintained by the 
Healthcare Cost Utilization Project (HCUP) (HCUP, 2020). The State Emergency Department 
Database (SEDD) collects information for each state regarding ED visits, while the State 
Inpatient Database (SID) does the same for inpatient admissions and discharges. These databases 
are available for each calendar year (HCUP, 2020).  
 Both databases will be accessed for the calendar year of 2018, which offers the most 
recent complete ED visit and hospital admission data for Florida (HCUP, 2020). The 
overwhelming majority of the data provided is aggregate in nature, but specific variables offer 
individual patient level data, which is essential in identifying those who have been admitted. In 
this case, data are offered based on individual information, but it has been encrypted and 




databases combined provide information regarding roughly 97 percent of the state data in these 
specific areas (HCUP, 2020).  
Database Outcome Measures 
 To expand both HCUP databases further, both are sponsored by the Agency for 
Healthcare research and Quality (AHRQ) and updated annually (HCUP, 2020). Both the SEDD 
and SID have over 100 clinical and non-clinical variables that are tracked and recorded including 
those related to International Classification of Diseases-10 (ICD-10) diagnostic codes, 
demographics, length of stay, and most importantly, financial charges. These data are provided 
for all ED visits and inpatient hospitalizations for community hospitals in the state (HCUP, 
2020).  
 Understanding this, two specific variables were identified as important for collecting 
visits to the ED for COPD exacerbations and for CHF admissions. This included the total annual 
costs, total annual charges, and total annual admissions for each medium sized hospital in 
Florida. This information could then be used in combination per each ICD-10 code relevant to 
the year to assess impact of ED for COPD exacerbations visits and CHF hospital admissions 
(HCUP, 2020).  
 Two different approaches were considered in defining patients presenting with COPD 
exacerbations or CHF admissions. In an effort to define patients with COPD exacerbations 
coming to the ED, those with primary diagnosis ICD-10 codes of J44.0-9 were included (CDC, 
2021). This encompasses conditions such as asthma with chronic obstructive pulmonary disease, 
chronic bronchitis with airways obstruction, chronic bronchitis with emphysema, and chronic 
obstructive tracheobronchitis (CDC, 2021). In an effort to define those with admission for CHF, 




wide variety of CHF conditions ranging from left, right and bilateral heart failure to acute and 
chronic ones (CDC, 2021). These were targeted as the primary outcome measures for both 
databases within Florida during the 2018 year.  
Study Population  
 The study population will involve all adult individuals age 18 years and older who visited 
an ED for an acute COPD exacerbation in 2018 or who was admitted to a hospital for a primary 
diagnosis of CHF. Those included will not be delineated based on state of residence because 
Florida is host to millions of tourists annually, many who stay for an extended number of months 
each year. In addition, some comparable research has excluded those that died during admission 
or in the ED in an effort to collect more accurate annual data (Hasegawa, Tsugawa, Tsai, Brown, 
& Camargo, 2014). However, since the purpose of this study is to simply measure cost per 
episode, these patients will be included in this study.  
 Other inclusion criteria have been defined in that patients visiting the ED with a COPD 
exacerbation or being admitted for CHF to the hospital must have primary discharge diagnoses 
that match the aforementioned ICD-10 codes listed. Secondary diagnostic codes will not be 
considered in this regard (Chamberlain, Sond, Mahendraraj, Lau, & Siracuse, 2018). Other 
patients in the cohort who have concurrent COPD issues or CHF problems with another primary 
condition will be excluded from the collection and analysis of the data.  
Statistical Analysis  
 In considering the analysis of the data, key pieces of data collected will include all visits 
to the ED for acute exacerbations of COPD during the calendar year 2018 in Florida, all 
admissions for CHF during the calendar year 2018 in Florida, and the average cost for each. 




(HCUP, 2020). The total charges for the aggregate ICD-10 codes for both CHF and COPD will 
then be added together before dividing these by the total number of hospital admission and ED 
visits respectively. This will provide an average cost for each ED visit and each CHF admission 
for comparison (Jiang, Xiao, Segal, Mobley, & Park, 2019). At the same time, aggregate costs, 
total charges, the mean and the average range for both total charges and total costs can be 
determined for the entire year for the state of Florida as well to assess the volume and overall 
expenditures in these areas. Both offer important insights that could drive effective changes.  
 Because this study seeks to simply explore overall costs for these two scenarios in the 
state of Florida, further analysis of the data will not be performed. If specific intervention related 
to demographic data, comorbidities, and other issues were being considered, then such data 
would be included in the collection process (Hasegawa, et al., 2014). However, in the current 
study, this data analysis is not required.  
Conclusion 
 The proposed methodology for this study aligns well with the intended purpose. It will 
explore the average cost per-patient in single admission for CHF patients, and ED admits for 
COPD patients to determine if whether these costs and hypotheses can be supported. State-
delineated databases will be accessed to collect information about ED visits for COPD 
exacerbations and hospital admissions within 30 days for CHF among adult populations in 
Florida during 2018. This data will then be compared to cost data for caring for these conditions 
in these settings at both aggregate and individual levels. This analysis will then provide results 
that will allow interpretations about where targeted strategies and services may be used to 





CHAPTER IV – RESULTS 
Data were collected for both congestive heart failure (CHF) admissions for the calendar 
year 2018, as were emergency department (ED) visits for chronic obstructive pulmonary disease 
(COPD). The data obtained included hospital IDs, total charges, total costs, and total 
admissions/ED visits. The data was then analyzed for both conditions using descriptive statistics 
that included the mean, median, and range of the data. This data analysis table is included in 
Appendix A for CHF data and Appendix B for COPD data.  
For CHF admissions, the total number of hospitals included in the data collection totaled 
182 facilities. Notably, the total charges mean and median for CHF admissions differ greatly 
($49M and $27M, respectively). Likewise, the mean and median for total costs ($7.7M and 
3.4M, respectively). Also, the range of costs per CHF admission was quite broad, with the mean 
exceeding the median significantly ($13K and $11K, respectively); this highlights the skewed 
distribution of the available data for all parameters; the total charges, total costs, and cost per 
CHF admissions for the calendar year 2018. Figure 1 shows a right skew for the number of CHF 
admissions; this data did not exhibit a normal distribution but was instead skewed to the right. 




hospitals in the sample size had higher volumes and cost per admission that resulted in higher 




Figure 1- CHF Admissions Averages per 25th, 50th, and 75th Quartiles at the Hospital-Level 
 
 



















































 In terms of the COPD, data collected and analyzed, and 163 hospitals were sampled for 
the year 2018. The COPD ER visits total charges mean and median differs notably ($5M and 
3.6M, respectively). Similar to the CHF data, the total cost for COPD-related ED visits mean and 
median showed a broad range ($353K and $278K, respectively). The range of ED visits and 
costs per visit exhibited a slightly broad range, and again, the mean values of both of these 
statistics exceeded median values ($700 and $599, respectively); this highlights the slightly 
skewed distribution of all these parameters for the calendar year 2018.  Figure 3 shows a right 
skew for the number of COPD visits, with most ED facilities experiencing a higher mean 
average than the median average of COPD ED visits. Figure 4 shows a right skew for COPD ER 
visits cost per admission. In essence, this indicated that some hospitals in the sample size had 
slightly higher volumes and cost per visit that results in a higher mean than the median.  
 
 
































Figure 4- COPD Costs/ED Visit Averages per 25th, 50th, and 75th Quartiles Averages at 
the Hospital-Level 
 Thus, the data analysis results revealed that a substantially high number of CHF-related 
admissions than COPD-related ED visits occur annually and that both are associated with high 
costs per admission/visit. In terms of magnitude, CHF admissions exceed COPD ED visits. 
Likewise, costs per healthcare encounter are also much more substantial for CHF-related 
admissions in comparison to COPD ED visits. In both cases, mean values tend to reflect more 
accurate statistics because of the data’s skewed nature. 
Table 1 summarizes the most important findings of the study. The total charges for CHF 
admissions and COPD visits were around ($9B and $822M, respectively). Likewise, the total 
costs for both conditions were ($1.4B and $57.5M, respectively). The annual total CHF 
admissions and COPD ER visits were (103.5K and 83K, respectively). The median cost per CHF 






























Condition Total Charges Total Cost Total Admits/ED Visits Median Cost per Admit/Visit 
CHF Admissions $8B $1.4B 103K $11K 
COPD ED Visits $822M $57.5M 83K $599K 
  






















CHAPTER V – DISCUSSION 
Telehealth for CHF and COPD patients presents unique perspectives to reduce CHF 
admissions, COPD ER visits, patient mortality, and improve quality of life and healthcare costs 
(Burdese et al., 2018). In the setting of the rising incidence of CHF admissions and COPD ED 
visits in the U.S and the scarce resources of health systems, our main goal was to evaluate and 
compare the total charges, total costs, total admissions/ED visits associated with these 
conditions. Our study is the first known study to quantify three important characteristics; the 
total charges, the total costs, and the total visits for the two conditions in medium-size hospitals 
in Florida in the calendar year 2018. Our study evaluated potential telehealth transitions based on 
cost efficacy when choosing between CHF admissions and COPD ED visits as the most likely 
intervention to reduce costs. 
For instance, we identified the highest values (maximum) of the three important metrics 
1) total charges, 2) total costs, 3) volume in the CHF admissions dataset in 2018, as shown in 
Table 2 below. 
Hospital ID Total charges Total Costs Total Admission 
6390690 630,137,825 109,521,396 5366 
 
Table 2-CHF Admission Total Charges, Total Costs and Total Admission for Hospital 
6390690 
In terms of COPD ER visits, the highest values of the total charges, total costs, and volume has 





Hospital ID Total charges Total Costs Total Admission 
6390690 $30,482,958 $3,008,140 2245 
 
Table 3-COPD ER Visits Total Charges, Total Costs and Total Admission for Hospital 
6390690 
The two hospitals in both tables have the same ID, which means that the highest total charges, 
total costs, and total admissions/ED visits exist in the same hospital in Florida in 2018.  
The study results demonstrate some notable findings in assessing the potential cost 
benefits of telehealth interventions for congestive heart failure (CHF) and chronic obstructive 
pulmonary disease (COPD). In comparing the total number of CHF admissions annually to the 
number of COPD emergency department (ED) visits per year, it is clear that CHF admissions 
reflect a larger volume. In essence, CHF admissions exceed COPD ED visits by roughly 25 
percent. From this perspective alone, cost-saving efforts would preferentially consider the higher 
volume condition. Based on the data, this indicates that interventions targeting CHF care would 
be a priority compared to COPD presently. 
 Of course, costs per encounter also play a role in making this determination. Lower 
volume health encounters that are more costly may deserve priority attention as well. In this 
regard, however, the data shows that costs for the mean CHF admission is around $13,257, while 
the mean cost for a COPD ED visit is only $707. Notably, CHF admissions are not only higher in 
occurrence when compared to COPD ED visits but much more costly per encounter. This too 
indicates targeted interventions to reduce healthcare encounters should focus on CHF strategies 




 This study did consider the cost of COPD admissions as well as part of its literature 
review but did not sample hospital data in this regard. Ample literature indicates, however, that 
ED visits related to COPD exacerbations are higher in number than COPD admissions. Research 
suggests that 82 percent of COPD admissions occur through the ED, with a much smaller 
number being directly admitted (Rezaee et al., 2018). Likewise, the average cost of a COPD 
admission is substantially less than that for CHF. Large analyses have indicated that the average 
cost for a COPD admission is just below $7,000 (Reman et al., 2020). Thus, the literature 
similarly supports the present findings indicating that CHF admission prevention deserves 
greater priority and attention.  
 Interestingly, the current findings align well with prior research examining the costs 
related to CHF admission data. In a large study, Kilgore and colleagues (2017) noted the average 
cost of a CHF admission was $14,631 with an average length of stay of five days. This is 
extremely close to the mean CHF hospitalization cost of $13,257 in the current dataset. The 
reproducibility of these literature findings further validates the interpretation of the existing data 
and the need to invest in CHF care strategies.  
 Understanding this, it is, therefore, worthwhile to determine whether telehealth 
interventions represent cost-effective solutions to address these concerns related to CHF 
admissions and readmissions. Notably, telehealth programs and remote care offers improved 
access to providers, better efficiency, and reduced travel costs for patients (Snoswell et al., 
2020). Likewise, research shows that telehealth has reduced healthcare visits and hospitalizations 
in a variety of conditions (Deasfernandes, 2020). Liu and colleagues (2016) also demonstrated 
telehealth services offer significant cost savings due to reduced length of stays and 




 Specific support for using telehealth to reduce CHF admissions and related costs does 
exist. Burdese and colleagues (2018) showed that telehealth reduced admission rates by two-
thirds and reduced costs by roughly 60 percent. These findings are further supported by research 
conducted by Lin and coworkers (2017), who found telehealth significantly reduced CHF 
admissions, CHF admission length of stays, and mortality. Thus, telehealth does seem to be a 
strong consideration in addressing the high-volume and high-costs of CHF admissions and 
readmissions.  
 One issue that arises in this regard is whether all CHF patients benefit from 
telehealthcare. From a fundamental perspective, telehealth monitoring improves self-
management skills, adherence to therapies, and early detection of exacerbations (Stammer, 
2018). But that does not mean it is necessarily cost-effective for all CHF patients. Overall, cost 
estimates for implementing telehealth monitoring services suggest these expenses are around 
$220 per month (Liu et al., 2016). These estimates align well with other researchers who 
suggested annual telehealth costs are approximately $2,100 (Vasilopoulou et al., 2017). While 
these costs are much less than a CHF admission, not all CHF patients are hospitalized on an 
annual basis.  
 Additional research has been performed that extrapolates cost savings with telehealth 
based on CHF severity. Liu and researchers (2016) found that telehealth services were quite cost-
effective for intermediate and severe CHF patients but not for mild ones. As noted from the 
current study’s dataset, the range of costs per CHF admission varied widely. The minimum cost 
per admission was $1,863 for some hospitals but as high as $110,331 for others. In the former 
group, it would appear telehealth costs would be greater than a single admission, and therefore 




 Based on these insights, it seems that telehealth services can be cost-effective and 
beneficial for those with moderate to severe CHF patients. These individuals have the highest 
risk of hospitalization and readmission after a 30-day discharge (Chamberlain et al., 2018). 
Selectively enrolling these categories of CHF patients into a telehealth program looks to offer 
significant cost savings while also advancing the quality of life, longevity, and self-management 
abilities (Stammer, 2018). The current study supports these types of strategies for healthcare 
providers and systems in better managing those with CHF.  
 While it has been noted that CHF admission volume and costs make it a priority over 
COPD ED visits and admissions, this does not imply telehealth might not also be beneficial for 
COPD care as well. The literature supports that telehealth services reduce COPD ED visits by a 
third and hospital readmission rates by half (Sanchez-Nieto et al., 2016; Kargiannakis et al., 
2017). Given that the average hospitalization costs for a COPD patient is roughly $7,000, the 
cost of implementing telehealth services might be worthwhile for some patients (Rehman et al., 
2020; Vasilopoulou et al., 2017). However, the current mean cost of an ED visit for a COPD 
patient was only $707.76, which would not justify telehealth expenses from an ED visit 
perspective alone. Like those with moderate to severe CHF, select COPD patients may be the 
ones to benefit from these services primarily.  
Proper management of CHF patients who are Medicare beneficiaries -before initial 
hospitalization- has the potential to reduce hospital admissions that cost our healthcare system a 
lot of money (Kilgore et al., 2017). Therefore, telehealth services could result in notable cost 
savings, especially to federal CMS reimbursement level and private payer level. In addition, 




advanced technologies available to overcome the shortages of health providers (MacQueen et al., 
2017). 
 Multiple meta-analyses and systematic reviews stated that home-telemonitoring for CHF 
patients decreases hospital admissions by 15–20 percent, patient mortality by 30–35 percent, and 
improved quality of life (Burdese et al., 2018). From the volume perspective, implementing 
telehealth services for medium-sized hospitals in Florida could reduce CHF admissions by 20 
percent in 2018. In other words, it could reduce CHF admissions from 103,533 to 82,826, which 
will reduce the overall total charges and costs. From the cost perspective, implementing 
telehealth services for CHF patient could result in around $1.8B in savings in 2018, considering 
the 20 percent piece of the 8B total charges.   
In terms of COPD ER visits, the literature supports that telehealth services reduce COPD 
ED visits by a third (Sanchez-Nieto et al., 2016; Kargiannakis et al., 2017). In other words, 
implementing telehealth services for medium-sized hospitals in Florida could reduce COPD ER 
visits from around 83,147 to 55,431, which will reduce the overall total charges significantly. 
From the cost perspective, telehealth could reduce the total charges by a third, which will be 
around $274M in savings annually. 
Applying these savings on the hospital's median level, the CHF cost per admits median 
was $11,087; therefore, using telehealth services could reduce CHF cost per admits by $2,217 
(20% reduction). Regarding COPD ER visits, telehealth services could reduce the cost per visit 
from $598 to $199 (1/3 reduction). 
Applying these savings to the hospital in Tables 1 & 2 above (hospital ID: 6390690) would result 
in 20 percent savings in the three metrics; total admission, total costs, and total charges in the 




Hospital ID Total Charges Savings Total Costs Savings Total Admission Reductions 
6390690 $126,027,565 $21,904,279 1,073 
 
Table 4-CHF Admission Total Charges Savings, Total Costs Savings and Total Admission 
Reductions for Hospital 6390690 
Table 5 shows the COPD ER visits savings in using telehealth services in the same hospital 
results in a one-third reduction in the three metrics.  
Hospital ID Total charges savings Total Costs savings Total COPD ED visits Reductions 
6390690 10,160,986 1,002,713 748 
 
Table 5-COPD ER Visits Total Charges Savings, Total Costs Savings and Total Visits 
Reductions for Hospital 6390690 
Understanding this, the hospital with ID 6390690 in the dataset could reduce their total 
charges by $126M results in decreasing total charges annually from ($630M to $504M). Also, 
for the COPD ER visits, this hospital could save $10M in total charges, which results in 
decreasing total charges from ($30M to $20M) approximately. In summary, one hospital in the 
dataset  could save $126M from CHF admissions in addition to the $10M from COPD ER visits 
that results in $136M in total savings in 2018.  
Limitations 
 The current study has limitations. While the sample size is large and includes several 
hospitals and healthcare systems, the dataset does not distinguish admissions and ED visits based 
on baseline patient severity. This information would be valuable given the need to define which 




cost-effective strategies. Likewise, the dataset did not offer insights about the length of stays 
related to CHF admissions or the percentage of COPD ED visits that resulted in later admissions. 
This information could have provided some indirect evidence of condition severity, revealing 
additional insights. Finally, the dataset is regionally based and may not reflect trends in other 
parts of the country or world. Applying these findings to other regions may be limited as a result.  
Future Research 
 Notably, future research needs to examine further the potential benefits of telehealth 
services among CHF and COPD patients in relation to admissions, readmission, and ED visits. 
Research regarding volumes and costs are improving, and evidence that both health conditions 
are deserving of better care interventions exists from the quality of life and resource cost 
perspectives. However, it remains unclear which patients may benefit the most from telehealth 
services, which telehealth services are most efficacious and cost-effective, and the intensity and 
duration of telehealth interventions required for optimal outcomes. Investing in research into 
these specific areas would help direct future care more efficiently.  
Conclusions 
 In conclusion, both CHF and COPD represent prevalent health conditions that utilize 
tremendous healthcare resources, limit the quality of life, and are advancing in both volume and 
severity. ED visits, admissions, and 30-day readmissions reflect some of the costliest care 
services provided to these patients and reducing these encounters could significantly improve 
healthcare costs and patient outcomes. Telehealth services offer the potential to reduce these 
encounters by improving self-management skills, detecting early declines, and promoting 
management adherence. The current study thus set out to determine whether telehealth services 




 The results of this study revealed both CHF admissions, and COPD ED visits occur 
commonly among hospitals in Florida. Findings also showed that costs associated with these 
events are substantial, with CHF costs being much greater overall. Based on this, CHF 
interventions deserve priority attention. Likewise, the literature supports that telehealth services 
can have a much greater impact on care and cost-savings for CHF patients, particularly those 
with moderate to severe CHF. In other words, the results in this sample revealed that both CHF 
admissions and COPD ER visit cost medium size hospitals in the state of Florida per year a lot of 
money ($8B and $822M, respectively). Telehealth services offer significant recurring annual 
cost savings for both conditions ($1.8B and $274M, respectively). CHF is larger in magnitude in 
terms of admissions and cost per admission. While future research into these areas is needed to 
guide telehealth care optimally, the current study supports its use in moderate to severe CHF 
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CHF Admissions, FL for Calendar year 2018 
Hospitals: 182 
 Total Charges Total Cost TotalAdmits Cost Per Admits 
 $8,967,053,733 $1,416,425,618 103,533 13,680.91 
Mean $49,269,526 $7,782,558 568.86 $13,257 
Median $27,047,394 $3,440,360 371.50 $11,087 
Minimum $12,292.00 $3,727.50 1.00 $1,863.75 
Maximum $630,137,825 $109,521,396 5366 $110,331 
Range $630,125,533 $109,517,668 5365 $108,467 
1st quartile (25th Percentile) $7,256,170 $1,186,925 126.75 $8,919.52 
Median Value (50th 
Percentile) 
$27,047,394 $3,440,360 371.50 $11,087 
3rd quartile (75th Percentile) $69,891,477 $10,655,409 864.50 $13,824 







COPD ED Visits, FL for Calendar year 2018 
Hospitals: 163 
 Total Charges Total Cost Total visits Cost Per visit 
 $822,495,878 $57,575,149 83,147 $692.45 
Mean $5,045,986 $353,221 510.10 $707.76 
Median $3,687,994 $278,054 425 $598.96 
Minimum $15,184 $4,594.41 26 $153.15 
Maximum $30,482,958 $3,008,140 2245 $2,370.90 
Range $30,467,774 $3,003,546 2219 $2,217.75 
1st quartile (25th 
Percentile) 
$1,682,152 $142,280 212.5 $470.58 
Median Value (50th 
Percentile) 
$3,687,994 $278,054 425 $598.96 
3rd quartile (75th 
Percentile) 
$6,649,586 $460,720 687.5 $778.15 
Interquartile Range $4,967,434 $318,439 475 $307.58 
 
 
 
 
 
 
